Pfizer Sizes Up Rx Industry; Will Wall Street See Bulk As Strategic Asset?
Executive Summary
Pfizer is heading past the $50 bil. revenue level in 2004, but its biggest challenge may be convincing investors that its staggering size offers a competitive advantage